Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Letermovir
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Jason A Roberts | Royal Brisbane and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
PK of Oral Letermovir in Adults with End-Stage Kidney Disease With/Without Dialysis
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Failure, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2025
Lead Product(s) : Letermovir
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Jason A Roberts | Royal Brisbane and Women's Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences Launches Anvimo
Details : Anvimo (letermovir), is CMV DNA terminase inhibitor small molecule drug candidate, which is indicated for the treatment of cytomegalovirus infection.
Product Name : Anvimo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 06, 2025
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 09, 2024
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir,Acyclovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Approves PREVYMIS for CMV Disease Prevention in High-Risk Kidney Transplant
Details : Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.
Product Name : Prevymis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 19, 2024
Lead Product(s) : Letermovir,Acyclovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.
Product Name : Prevymis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.
Product Name : Prevymis
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2023
Lead Product(s) : Letermovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable